Clinical Trials Logo

Relapsed AML clinical trials

View clinical trials related to Relapsed AML.

Filter by:
  • None
  • Page 1

NCT ID: NCT05226468 Active, not recruiting - Clinical trials for Advanced Solid Tumor

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Start date: April 25, 2022
Phase: Phase 1
Study type: Interventional

This is an early phase clinical study using NEI-01 as single agent in oncology indication. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of NEI-01 and find out recommended dose of NEI-01 in solid tumor patient. Part 2: This part is extended dose design to determine the effectiveness of NEI-01 in in solid tumor and acute myeloid leukemia patients.

NCT ID: NCT03560908 Withdrawn - Relapsed AML Clinical Trials

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Start date: July 1, 2018
Phase: Phase 1
Study type: Interventional

In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled. Dasatinib 70 mg twice a day will be administrated for two weeks from day 1 of re-induction chemotherapy. The purpose of current study is to determine the clinical efficacy and tolerability of combination therapy of dasatinib with multi-agent chemotherapy in relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation.

NCT ID: NCT03516760 Terminated - Clinical trials for Acute Myeloid Leukemia

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Start date: April 11, 2018
Phase: Phase 1
Study type: Interventional

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.

NCT ID: NCT02675478 Completed - Refractory AML Clinical Trials

Phase 1 Study of Quizartinib

Start date: February 2016
Phase: Phase 1
Study type: Interventional

This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.